Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Trial details
- Registry ID
- NCT06207370
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for BabesiosisNCT06207370 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Recruiting | 2027-03-01Estimated |
| Long-Term Safety Study of TafenoquineNCT03320174 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Completed | 2021-07-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |